Novel immune check-point regulators in tolerance maintenance

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Guo, Yanxia ^a   Wang, Adele Y ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

B7; Butyrophilin; Immune tolerance

Indexed keywords

B7 ANTIGEN; BUTYROPHILIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; V DOMAIN IG SUPPRESSOR OF T CELL ACTIVATION PROTEIN; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

AUTOIMMUNITY; CLINICAL PRACTICE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MRNA EXPRESSION ASSAY; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84941266893     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00421     Document Type: Review

References (62)

1. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517-26. doi:10.1056/NEJMoa1104621.
2. Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol (2015) 33:1191-6. doi:10.1200/JCO.2014.56.6018.
3. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 372:2018-28. doi:10.1056/NEJMoa1501824.
4. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372:2521-32. doi:10.1056/NEJMoa1503093.
5. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 349:1907-15. doi:10.1056/NEJMoa035075.
6. Genovese MC, Becker JC, SchiffM, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 353:1114-23. doi:10.1056/NEJMoa050524.
7. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 10:535-46. doi:10.1111/j.1600-6143.2009.03005.x.
8. Chandrasekharan D, Issa F, Wood KJ. Achieving operational tolerance in transplantation: how can lessons from the clinic inform research directions? Transpl Int (2013) 26:576-89. doi:10.1111/tri.12081.
9. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 13:227-42. doi:10.1038/nri3405.
10. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol (2014) 10:14-24. doi:10.1038/nrneph.2013.183.
11. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 18:863-73. doi:10.1016/S1074-7613(03)00147-X.
12. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 18:849-61. doi:10.1016/S1074-7613(03)00152-3.
13. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 100:10388-92. doi:10.1073/pnas.1434299100.
14. Suh WK, Wang S, Duncan GS, Miyazaki Y, Cates E, Walker T, et al. Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol (2006) 26:6403-11. doi:10.1128/MCB.00755-06.
15. Azuma T, Zhu G, Xu H, Rietz AC, Drake CG, Matteson EL, et al. Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med (2009) 6:e1000166. doi:10.1371/journal.pmed.1000166.
16. Wang X, Hao J, Metzger DL, Ao Z, Meloche M, Verchere CB, et al. B7-H4 pathway in islet transplantation and beta-cell replacement therapies. J Transplant (2011) 2011:418902. doi:10.1155/2011/418902.
17. Wang X, Hao J, Metzger DL, Mui A, Ao Z, Akhoundsadegh N, et al. Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 60:3246-55. doi:10.2337/db11-0375.
18. Lee IF, Wang X, Hao J, Akhoundsadegh N, Chen L, Liu L, et al. B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice. Cell Immunol (2013) 282:1-8. doi:10.1016/j.cellimm.2013.03.005.
19. Zhu G, Augustine MM, Azuma T, Luo L, Yao S, Anand S, et al. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood (2009) 113:1759-67. doi:10.1182/blood-2008-01-133223.
20. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 208:577-92. doi:10.1084/jem.20100619.
21. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc Natl Acad Sci U S A (2014) 111:14846-51. doi:10.1073/pnas.1407447111.
22. Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye JJ, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J Clin Invest (2014) 124:1966-75. doi:10.1172/JCI74589.
23. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 74:1924-32. doi:10.1158/0008-5472.CAN-13-1504.
24. Franke WW, Heid HW, Grund C, Winter S, Freudenstein C, Schmid E, et al. Antibodies to the major insoluble milk fat globule membrane-associated protein: specific location in apical regions of lactating epithelial cells. J Cell Biol (1981) 89:485-94. doi:10.1083/jcb.89.3.485.
25. Heid HW, Winter S, Bruder G, Keenan TW, Jarasch ED. Butyrophilin, an apical plasma membrane-associated glycoprotein characteristic of lactating mammary glands of diverse species. Biochim Biophys Acta (1983) 728:228-38. doi:10.1016/0005-2736(83)90476-5.
26. Stefferl A, Schubart A, Storch M, Amini A, Mather I, Lassmann H, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol (2000) 165:2859-65. doi:10.4049/jimmunol.165.5.2859.
27. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A. Butyrophilins: an emerging family of immune regulators. Trends Immunol (2011) 33:34-41. doi:10.1016/j.it.2011.09.007.
28. Tazi-Ahnini R, Henry J, Offer C, Bouissou-Bouchouata C, Mather IH, Pontarotti P. Cloning, localization, and structure of new members of the butyrophilin gene family in the juxta-telomeric region of the major histocompatibility complex. Immunogenetics (1997) 47:55-63. doi:10.1007/s002510050326.
29. Ikemizu S, Gilbert RJ, Fennelly JA, Collins AV, Harlos K, Jones EY, et al. Structure and dimerization of a soluble form of B7-1. Immunity (2000) 12:51-60. doi:10.1016/S1074-7613(00)80158-2.
30. Arnett HA, Escobar SS, Viney JL. Regulation of costimulation in the era of butyrophilins. Cytokine (2009) 46:370-5. doi:10.1016/j.cyto.2009.03.009.
31. Arnett HA, Viney JL. Immune modulation by butyrophilins. Nat Rev Immunol (2014) 14:559-69. doi:10.1038/nri3715.
32. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol (2006) 176:7354-60. doi:10.4049/jimmunol.176.12.7354.
33. Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, et al. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J Immunol (2007) 178:1523-33. doi:10.4049/jimmunol.178.3.1523.
34. Yamazaki T, Goya I, Graf D, Craig S, Martin-Orozco N, Dong C. A butyrophilin family member critically inhibits T cell activation. J Immunol (2010) 185:5907-14. doi:10.4049/jimmunol.1000835.
35. Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget (2010) 1:329-38.
36. Chapoval AI, Smithson G, Brunick L, Mesri M, Boldog FL, Andrew D, et al. BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. Mol Immunol (2013) 56:819-28. doi:10.1016/j.molimm.2013.08.003.
37. Aigner J, Villatoro S, Rabionet R, Roquer J, Jimenez-Conde J, Marti E, et al. A common 56-kilobase deletion in a primate-specific segmental duplication creates a novel butyrophilin-like protein. BMC Genet (2013) 14:61. doi:10.1186/1471-2156-14-61.
38. Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, Mes-Masson AM. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 17:913-20. doi:10.1158/1055-9965.EPI-07-0692.
39. Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One (2012) 7:e38541. doi:10.1371/journal.pone.0038541.
40. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol (2013) 14:908-16. doi:10.1038/ni.2665.
41. Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells. Immunity (2014) 40:490-500. doi:10.1016/j.immuni.2014.03.003.
42. Bas A, Swamy M, Abeler-Dorner L, Williams G, Pang DJ, Barbee SD, et al. Butyrophilin-like 1 encodes an enterocyte protein that selectively regulates functional interactions with T lymphocytes. Proc Natl Acad Sci U S A (2010) 108:4376-81. doi:10.1073/pnas.1010647108.
43. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 37:357-64. doi:10.1038/ng1519.
44. Price P, Santoso L, Mastaglia F, Garlepp M, Kok CC, Allcock R, et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens (2004) 64:575-80. doi:10.1111/j.1399-0039.2004.00310.x.
45. Mochida A, Kinouchi Y, Negoro K, Takahashi S, Takagi S, Nomura E, et al. Butyrophilin-like 2 gene is associated with ulcerative colitis in the Japanese under strong linkage disequilibrium with HLA-DRB1*1502. Tissue Antigens (2007) 70:128-35. doi:10.1111/j.1399-0039.2007.00866.x.
46. Pathan S, Gowdy RE, Cooney R, Beckly JB, Hancock L, Guo C, et al. Confirmation of the novel association at the BTNL2 locus with ulcerative colitis. Tissue Antigens (2009) 74:322-9. doi:10.1111/j.1399-0039.2009.01314.x.
47. Juyal G, Prasad P, Senapati S, Midha V, Sood A, Amre D, et al. An investigation of genome-wide studies reported susceptibility loci for ulcerative colitis shows limited replication in north Indians. PLoS One (2011) 6:e16565. doi:10.1371/journal.pone.0016565.
48. Moller M, Kwiatkowski R, Nebel A, Van Helden PD, Hoal EG, Schreiber S. Allelic variation in BTNL2 and susceptibility to tuberculosis in a South African population. Microbes Infect (2007) 9:522-8. doi:10.1016/j.micinf.2007.01.011.
49. Orozco G, Eerligh P, Sanchez E, Zhernakova S, Roep BO, Gonzalez-Gay MA, et al. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum Immunol (2005) 66:1235-41. doi:10.1016/j.humimm.2006.02.003.
50. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol (2009) 50:1247-57. doi:10.1016/j.jhep.2009.03.006.
51. Svendsen UG, Aggestrup S, Heilmann C, Jacobsen N, Koch C, Larsen B, et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur Respir J (1995) 8:334-7. doi:10.1183/09031936.95.08020334.
52. Comerci GD Jr, Williams TM, Kellie S. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J Heart Lung Transplant (2009) 28:743-5. doi:10.1016/j.healun.2009.04.011.
53. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int (2006) 19:885-92. doi:10.1111/j.1432-2277.2006.00388.x.
54. Delis S, Ciancio G, Burke GW III, Garcia-Morales R, Miller J. Donor bone marrow transplantation: chimerism and tolerance. Transpl Immunol (2004) 13:105-15. doi:10.1016/j.trim.2004.05.006.
55. Parulekar AD, Boomer JS, Patterson BM, Yin-Declue H, Deppong CM, Wilson BS, et al. A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med (2013) 187:494-501. doi:10.1164/rccm.201207-1205OC.
56. Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology (2008) 71:917-24. doi:10.1212/01.wnl.0000325915.00112.61.
57. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 143(62-69):e64. doi:10.1053/j.gastro.2012.04.010.
58. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 5:443-53. doi:10.1111/j.1600-6143.2005.00749.x.
59. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 10:547-57. doi:10.1111/j.1600-6143.2010.03016.x.
60. Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 2:17ra10. doi:10.1126/scitranslmed.3000116.
61. Badell IR, Thompson PW, Turner AP, Russell MC, Avila JG, Cano JA, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant (2012) 12:126-35. doi:10.1111/j.1600-6143.2011.03736.x.
62. Bekiaris V, Sedy JR, Macauley MG, Rhode-Kurnow A, Ware CF. The inhibitory receptor BTLA controls gammadelta T cell homeostasis and inflammatory responses. Immunity (2013) 39:1082-94. doi:10.1016/j.immuni.2013.10.017.